Will our cardiomyopathy patients accept gene therapy?

P. A. Doevendans*, C. Kupatt, M. Giacca, P. Glijnis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Novel techniques such as gene therapy are becoming available in an attempt to cure inherited diseases. Before these new therapies can be offered to patients, we need to be aware of potential reservations or objections, not only from patients and their surroundings but also from the public. In addition, legal issues and costs need attention before curative gene therapy can be applied in the clinic. As this therapeutic approach is closer to becoming a reality, now is the right time to start the debate.

Original languageEnglish
Pages (from-to)343-344
Number of pages2
JournalNetherlands Heart Journal
Issue number7-8
Publication statusPublished - Jul 2022


  • Cardiomyopathy
  • Gene editing
  • Viral vectors


Dive into the research topics of 'Will our cardiomyopathy patients accept gene therapy?'. Together they form a unique fingerprint.

Cite this